TimesSquare Mid Cap Growth Strategy Picks Ionis Pharmaceuticals (IONS) on Clinical Momentum
TimesSquare Capital Management, an equity investment management company, released its “U.S.
Ionis Pharmaceuticals Inc (IONS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 5,857,629 | $439,849,362 | +92% | 0.35% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,047,727 | $153,763,820 | +15% | 0.88% |
| 3. | Deerfield Management James E. Flynn | 1,979,669 | $148,653,345 | 1.75% | |
| 4. | Deep Track Capital David Kroin | 1,950,000 | $146,425,500 | +15% | 2.39% |
| 5. | 60,000,000 | $90,613,860 | 1.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.86 | 15,000 | $477,900.00 | 50,219 | 2025-05-01 | Filing | |
| $36.23 | 2,500 | $90,583.00 | 35,219 | 2024-12-23 | Filing | |
| $36.20 | 2,500 | $90,495.75 | 32,719 | 2024-12-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $80.16 | 5,635 | $451,698.78 | 4,669 | 2026-06-26 | Filing | |
| $80.00 | 3,069 | $245,520.00 | 61,470 | 2026-06-26 | Filing | |
| $81.05 | 26,000 | $2,107,196.00 | 77,114 | 2026-06-26 | Filing | |
| $80.59 | 50,000 | $4,029,500.00 | 245,571 | 2026-06-26 | Filing | |
| $78.49 | 21,072 | $1,653,941.28 | 245,571 | 2026-06-25 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,460 | $115,763 | 0.01% | |
| 2. | 300 | $23,787 | 0% | |
| 3. | 223 | $17,682 | 0% | |
| 4. | 90 | $7,136 | 0% | |
| 5. | 203 | $16 | 0% |
News See All
8 Best Genomics Stocks to Buy According to Analysts
On June 8, 2026, Google DeepMind, Google.org, and the Wellcome Sanger Institute announced a five-year artificial intelligence collaboration for genomics.
8 Most Promising Biotech Stocks to Buy Now
On January 14, Reuters reported that investors foresee a comeback in the US biotech sector in 2026, with more IPO activity and stronger deal-making as legislative risks ease.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2026 Earnings Call Transcript
Operator: Good day, and welcome to Ionis' First Quarter 2020 Financial Results Conference Call. As a reminder, this call is being recorded.
Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target
As of March 13, 2026, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) carried a Moderate Buy consensus on Wall Street.
11 Best Growth Stocks to Invest in According to Billionaires
Infotech and biotech remain two of the clearer growth pockets because the underlying spending data is still expanding.
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best strong buy healthcare stocks to invest in. Ionis Pharmaceuticals, Inc.
11 Best Strong Buy Healthcare Stocks to Invest In
On February 23, Steven Wieting, CIO Group chief investment strategist, appeared on CNBC’s ‘The Exchange’ to talk about the stock market and the recent price action in stocks.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2025 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2025 Earnings Call Transcript February 25, 2026Ionis Pharmaceuticals, Inc. misses on earnings expectations.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the Ionis Pharmaceuticals, Inc. Third Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded.
Hedge Fund Resource Center